Efficacy of anakinra in reducing progression to organ dysfunction in patients with pneumonia (INSPIRE): a randomised, double-blind, placebo-controlled phase IIa trial
The Lancet Regional Health - Europe 2026
2
January, 2026
26
February, 2025
Recent advances of precision immunotherapy in sepsis
Antonios Arapis, Dimitrios Panagiotopoulos, Evangelos J. Giamarellos-Bourboulis Burns & Trauma, 2025, 13, tkaf001 DOI: 10.1093/burnst/tkaf001Download pdf 🡇 Keywords: Precision immunotherapy; Sepsis; Anakinra; Nangibotide; Nivolumab; Interferon-gamma; Growth factors; Adrecizumab
10
January, 2025
Anakinra Efficacy in COVID-19 Pneumonia Guided by Soluble Urokinase Plasminogen Activator Receptor: Association With the Inflammatory Burden of the Host
Evdoxia Kyriazopoulou, Karolina Akinosoglou, Eleni Florou, Elli Kouriannidi, Artemis Bogosian, Olga Tsachouridou, Konstantinos N. Syrigos, Nikolaos Gatselis, Haralampos Milionis, Ilias C. Papanikolaou, Styliani Sympardi, Maria Dafni, Antonia Alevizou, Alexia-Vasiliki Amvrazi, Errika Alexandrou, Kyprianos Archontoulis, Katerina Argyraki, Zoi Alexiou, Yakinthi Georgiou, Dimitra Gkogka, Foteini Kyrailidi, Vassiliki Kalyva, Triantafilli Nikolopoulou, Sofia Ioannou, Petros Bakakos, Georgia Karathanassiou,
14
March, 2024
Transitions of blood immune endotypes and improved outcome by anakinra in COVID-19 pneumonia: an analysis of the SAVE-MORE randomized controlled trial
Evdoxia Kyriazopoulou, Yehudit Hasin‐Brumshtein, Uros Midic, Garyfallia Poulakou, Haralampos Milionis, Simeon Metallidis, Myrto Astriti, Archontoula Fragkou, Aggeliki Rapti, Eleonora Taddei, Ioannis Kalomenidis, Georgios Chrysos, Andrea Angheben, Ilias Kainis, Zoi Alexiou, Francesco Castelli, Francesco Saverio Serino, Petros Bakakos, Emanuele Nicastri, Vasiliki Tzavara, Sofa Ioannou, Lorenzo Dagna, Katerina Dimakou, Glykeria Tzatzagou, Maria Chini, Matteo Bassetti, Vasileios
1
September, 2023
PRECISION
HISS: Facing the LONG-COVID syndrome Ongoing study Official Study Title Safety and efficacy of Anakinra treatment for patients with Persistent REspiratory symptoms post-acute COVID and Immune System activatION: the PRECISION double-blind, randomized clinical trial Brief Description The effect of the drug anakinra in the treatment of long-term complications after COVID-19. The
27
December, 2022
Efficacy and safety of early soluble urokinase plasminogen receptor plasma-guided anakinra treatment of COVID-19 pneumonia: A subgroup analysis of the SAVE-MORE randomised trial
Karolina Akinosoglou, Antigone Kotsaki, Ioanna-Maria Gounaridi, Eirini Christaki, Simeon Metallidis, Georgios Adamis, Archontoula Fragkou, Massimo Fantoni, Aggeliki Rapti, Ioannis Kalomenidis, Georgios Chrysos, Gloria Boni, Ilias Kainis, Zoi Alexiou, Francesco Castelli, Francesco Saverio Serino, Petros Bakakos, Emanuele Nicastri, Vassiliki Tzavara, Asimina Safarika, Sofia Ioannou, Lorenzo Dagna, Katerina Dimakou, Glykeria Tzatzagou, Maria Chini, Matteo Bassetti, Vasileios
19
December, 2022
Interferon gamma-induced protein 10 (IP-10) for the early prognosis of the risk for severe respiratory failure and death in COVID-19 pneumonia
Charilaos Samaras, Evdoxia Kyriazopoulou, Garyfallia Poulakou, Eran Reiner, Maria Kosmidou, Ioanna Karanika, Vasileios Petrakis, George Adamis, Nikolaos K. Gatselis, Archontoula Fragkou, Aggeliki Rapti, Eleonora Taddei, Ioannis Kalomenidis, George Chrysos, Giulia Bertoli, Ilias Kainis, Zoi Alexiou, Francesco Castelli, Francesco Saverio Serino, Petros Bakakos, Emanuele Nicastri, Vassiliki Tzavara, Evangelos Kostis, Lorenzo Dagna, Sofia Koukidou, Glykeria Tzatzagou,
1
November, 2022
Toward personalized immunotherapy in sepsis: The PROVIDE randomized clinical trial
Konstantinos Leventogiannis, Evdoxia Kyriazopoulou, Nikolaos Antonakos, Antigone Kotsaki, Iraklis Tsangaris, Dimitra Markopoulou, Inge Grondman, Nikoleta Rovina, Vassiliki Theodorou, Eleni Antoniadou, Ioannis Koutsodimitropoulos, George Dalekos, Glykeria Vlachogianni, Karolina Akinosoglou, Vassileios Koulouras, Apostolos Komnos, Theano Kontopoulou, Athanassios Prekates, Antonia Koutsoukou, Jos WM van der Meer, George Dimopoulos, Miltiades Kyprianou, Mihai G Netea, Evangelos J. Giamarellos-Bourboulis
10
October, 2022
INSPIRE
Completed study 🡇 Download protocol 🡇 Download SAP Official Study Title Immunotherapy Navigated by Serum Presepsin for Infections of the REspiratory tract: the INSPIRE double-blind, randomized, phase IIa exploratory trial Brief Description The INSPIRE study is an exploratory, randomised, phase IIa clinical trial which aims to evaluate the potential benefit of presepsin-guided anakinra therapy
1
October, 2021
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial
Evdoxia Kyriazopoulou, Garyfallia Poulakou, Haralampos Milionis, Simeon Metallidis, Georgios Adamis, Konstantinos Tsiakos, Archontoula Fragkou, Aggeliki Rapti, Christina Damoulari, Massimo Fantoni, Ioannis Kalomenidis, Georgios Chrysos, Andrea Angheben, Ilias Kainis, Zoi Alexiou, Francesco Castelli, Francesco Saverio Serino, Maria Tsilika, Petros Bakakos, Emanuele Nicastri, Vassiliki Tzavara, Evangelos Kostis, Lorenzo Dagna, Panagiotis Koufargyris, Katerina Dimakou, Spyridon Savvanis, Glykeria